Format

Send to

Choose Destination
Breast Cancer Res Treat. 2000 Nov;64(2):189-91.

Polyadenylic-polyuridylic acid plus locoregional radiotherapy versus chemotherapy with CMF in operable breast cancer: a 14 year follow-up analysis of a randomized trial of the Fédération Nationale des Centres de Lutte contre le Cancer (FNCLCC).

Author information

1
Département de Biostatistique et d'Epidémiologie, Institut G ustave-Roussy, Villejuif, France. agnes.laplanche@igr.fr

Abstract

With a median follow-up of 14 years, the combination of polyadenylic-polyuridylic acid plus locoregional radiotherapy (257 patients) has significantly improved disease-free survival (p = 0.03) and significantly reduced the incidence of metastases (p = 0.04) when compared to CMF alone (260 patients), in women with operable breast cancer. The trial does not, however, permit an appreciation of the respective role of radiotherapy and PolyAU in these results.

PMID:
11194454
DOI:
10.1023/a:1006498121628
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center